See more : Far East Consortium International Limited (FRTCF) Income Statement Analysis – Financial Results
Complete financial analysis of ChengDu ShengNuo Biotec Co.,Ltd. (688117.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChengDu ShengNuo Biotec Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Bodhi Tree Multimedia Limited (BTML.NS) Income Statement Analysis – Financial Results
- DPCM Capital, Inc. (XPOA) Income Statement Analysis – Financial Results
- Piramal Pharma Limited (PPLPHARMA.BO) Income Statement Analysis – Financial Results
- Seer, Inc. (SEER) Income Statement Analysis – Financial Results
- Kolon Life Science Inc. (102940.KQ) Income Statement Analysis – Financial Results
ChengDu ShengNuo Biotec Co.,Ltd. (688117.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.snbiopharm.com
About ChengDu ShengNuo Biotec Co.,Ltd.
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 435.02M | 395.72M | 386.53M | 378.77M | 326.74M | 277.97M | 194.45M |
| Cost of Revenue | 163.38M | 136.64M | 108.33M | 78.76M | 64.96M | 82.39M | 65.79M |
| Gross Profit | 271.64M | 259.08M | 278.20M | 300.01M | 261.78M | 195.58M | 128.66M |
| Gross Profit Ratio | 62.44% | 65.47% | 71.97% | 79.21% | 80.12% | 70.36% | 66.17% |
| Research & Development | 29.05M | 23.29M | 13.75M | 18.25M | 11.10M | 15.68M | 14.47M |
| General & Administrative | 29.36M | 18.52M | 19.07M | 16.30M | 11.32M | 15.60M | 10.80M |
| Selling & Marketing | 105.03M | 113.24M | 151.73M | 181.84M | 166.74M | 114.31M | 50.00M |
| SG&A | 161.32M | 131.76M | 170.80M | 198.13M | 178.07M | 129.91M | 60.80M |
| Other Expenses | 169.11K | 26.83M | 18.59M | 7.81M | 7.66M | -30.75K | 161.59K |
| Operating Expenses | 190.54M | 181.88M | 203.14M | 224.19M | 196.82M | 156.34M | 83.07M |
| Cost & Expenses | 353.92M | 318.52M | 311.47M | 302.95M | 261.78M | 238.73M | 148.86M |
| Interest Income | 3.66M | 2.10M | 2.74M | 1.53M | 738.66K | 540.88K | 132.56K |
| Interest Expense | 9.08M | 3.50M | 170.76K | 18.70K | 698.08K | 1.05M | 748.71K |
| Depreciation & Amortization | 27.65M | 25.95M | 18.75M | 17.29M | 13.29M | 12.70M | 12.13M |
| EBITDA | 116.85M | 103.79M | 89.51M | 86.29M | 70.39M | 47.76M | 52.24M |
| EBITDA Ratio | 26.86% | 27.53% | 23.67% | 24.63% | 23.54% | 19.07% | 28.73% |
| Operating Income | 81.10M | 72.84M | 75.81M | 69.79M | 57.55M | 34.44M | 39.20M |
| Operating Income Ratio | 18.64% | 18.41% | 19.61% | 18.42% | 17.61% | 12.39% | 20.16% |
| Total Other Income/Expenses | -979.58K | -477.20K | -5.32M | -907.20K | -1.24M | -30.75K | 161.59K |
| Income Before Tax | 80.12M | 72.36M | 70.49M | 68.88M | 56.32M | 34.41M | 39.36M |
| Income Before Tax Ratio | 18.42% | 18.29% | 18.24% | 18.19% | 17.24% | 12.38% | 20.24% |
| Income Tax Expense | 9.80M | 7.88M | 9.24M | 8.88M | 8.18M | 4.55M | 5.46M |
| Net Income | 70.34M | 64.48M | 61.25M | 60.00M | 48.13M | 29.86M | 33.90M |
| Net Income Ratio | 16.17% | 16.30% | 15.85% | 15.84% | 14.73% | 10.74% | 17.43% |
| EPS | 0.63 | 0.58 | 0.55 | 0.54 | 0.43 | 0.36 | 0.41 |
| EPS Diluted | 0.63 | 0.58 | 0.55 | 0.54 | 0.43 | 0.36 | 0.41 |
| Weighted Avg Shares Out | 111.65M | 112.00M | 112.00M | 112.00M | 112.00M | 81.97M | 81.83M |
| Weighted Avg Shares Out (Dil) | 112.00M | 112.00M | 112.00M | 112.00M | 112.00M | 81.97M | 81.83M |
Source: https://incomestatements.info
Category: Stock Reports